Can a tailored drug combo improve early response in chronic myeloid leukemia?
Disease control
Not yet recruiting
This phase II trial tests asciminib as the first treatment for adults newly diagnosed with chronic myeloid leukemia in chronic phase. Patients with unfavorable risk factors also receive dasatinib starting four weeks later. The study measures how many patients achieve a major mole…
Phase 2 • Sponsor: Prof. Dr. med. Andreas Hochhaus • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC